Your browser doesn't support javascript.
loading
Prevalence and outcome of Covid-19 infection in cancer patients: a national VA study
Nathanael R Fillmore; Jennifer La; Raphael E Szalat; David P Tuck; Vinh Nguyen; Cenk Yildirim; Nhan V Do; Mary T Brophy; Nikhil C Munshi.
Affiliation
  • Nathanael R Fillmore; VA Boston Healthcare System, Harvard Medical School, Dana-Farber Cancer Institute
  • Jennifer La; VA Boston Healthcare System
  • Raphael E Szalat; VA Boston Healthcare System, Dana-Farber Cancer Institute, Boston University School of Medicine
  • David P Tuck; VA Boston Healthcare System, Boston University School of Medicine
  • Vinh Nguyen; VA Boston Healthcare System
  • Cenk Yildirim; VA Boston Healthcare System
  • Nhan V Do; VA Boston Healthcare System, Boston University School of Medicine
  • Mary T Brophy; VA Boston Healthcare System, Boston University School of Medicine
  • Nikhil C Munshi; VA Boston Healthcare System, Harvard Medical School, Dana-Farber Cancer Institute
Preprint in English | medRxiv | ID: ppmedrxiv-20177923
ABSTRACT
BackgroundEmerging data suggest variability in susceptibility and outcome to Covid-19 infection. Identifying the risk-factors associated with infection and outcomes in cancer patients is necessary to develop healthcare recommendations. MethodsWe analyzed electronic health records of the US National Veterans Administration healthcare system and assessed the prevalence of Covid-19 infection in cancer patients. We evaluated the proportion of cancer patients tested for Covid-19 and their confirmed positivity, with clinical characteristics, and outcome, and stratified by demographics, comorbidities, cancer treatment and cancer type. ResultsOf 22914 cancer patients tested for Covid-19, 1794 (7.8%) were positive. The prevalence of Covid-19 was similar across all ages. Higher prevalence was observed in African-American (AA) (15%) compared to white (5.5%; P<.001), in Hispanic vs non-Hispanic population and in patients with hematologic malignancy compared to those with solid tumors (10.9% vs 7.7%; P<.001). Conversely, prevalence was lower in current smoker patients, patients with other co-morbidities and having recently received cancer therapy (< 6 months). The Covid-19 attributable mortality was 10.9%. Highest mortality rates were observed in older patients, those with renal dysfunction, higher Charlson co-morbidity score and with certain cancer types. Recent (< 6 months) or past treatment did not influence mortality. Importantly, AA patients had 3.5-fold higher Covid-19 attributable hospitalization, however had similar mortality rate as white patients. ConclusionPre-existence of cancer affects both susceptibility to Covid-19 infection and eventual outcome. The overall Covid-19 attributable mortality in cancer patients is affected by age, co-morbidity and specific cancer types, however, race or recent treatment including immunotherapy does not impact outcome. FundingsVA Office of Research and Development and National Institutes of Health.
License
cc0
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Observational study / Prognostic study Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Observational study / Prognostic study Language: English Year: 2020 Document type: Preprint
...